A New Way To Tackle Deal Valuations: Infectious Disease As A Case Study
Executive Summary
Despite regulatory uncertainty, the growing problem of antibiotic resistance – especially for gram-negative organisms – has forced big drug companies to take renewed interest in novel anti-infectives.